SFDA Expedited Drug Approval: Impact on Saudi Pharma Market & Innovation
The SFDA's expedited drug approval process is revolutionizing the Saudi pharmaceutical market, fostering innovation and enhancing access to vital medications.
Quick Answer
The SFDA's expedited drug approval process is revolutionizing the Saudi pharmaceutical market, fostering innovation and enhancing access to vital medications.
Key Questions
- What are the SFDA's expedited drug approval pathways?
- How much have review timelines been reduced by using SFDA expedited pathways?
- What percentage of novel drugs in Saudi Arabia are approved via expedited pathways?
- How does the SFDA's approval timeline compare to the FDA's?
The Saudi Food and Drug Authority (SFDA) has built a multi-track expedited drug approval framework that is cutting median review timelines to 248 days—on par with the U.S. FDA. With over half of novel drugs now cleared through accelerated pathways, the system is reshaping patient access and foreign investment in the Kingdom's pharmaceutical market.
Contents9 sections
Key Takeaways
- A 2026 SFDA-sponsored study found a median approval time of 248 days for novel drugs, nearly matching the FDA's 243-day median. Algabbani et al., 2026
- The Verification pathway targets 30 working days for products already approved by both the FDA and EMA, while the Abridged pathway aims for 60 working days. SFDA Verification & Abridged Guidance v2.2
- Priority review, introduced in 2014, reduces assessment timelines by approximately 40% for drugs addressing serious or life-threatening conditions. SFDA Priority Review Guidance v5.3
- 52.17% of drug approvals in the study cohort used an expedited review pathway, reflecting strong industry uptake of reliance-based routes. Algabbani et al., 2026
- The Breakthrough Medicines Program launched in October 2023, adding early-dialogue acceleration for innovative therapies still in Phase II development. SFDA BMP Guidance v1.0
What Expedited Pathways Does the SFDA Offer?
The SFDA operates six distinct expedited routes, each targeting a different gap in patient access. The table below summarizes eligibility, review targets, and reliance requirements.
| Pathway | Eligibility | Target Timeline | Reliance Basis |
|---|---|---|---|
| Verification | Approved by FDA and EMA | 30 working days | FDA + EMA approval |
| Abridged | Approved by FDA or EMA | 60 working days | One SRA approval |
| Priority Review | Serious conditions; unmet need; first biosimilar; shortage drugs | ~40% reduction | Full SFDA assessment |
| Breakthrough Medicines | Serious or life-threatening; substantial improvement over standard | 60 working days (assessment) | Early dialogue; rolling review |
| Orphan Drug Designation | Rare diseases (prevalence < 1 in 50,000) | Fee incentives; expedited review | Full SFDA assessment |
| Conditional Approval | Strong preliminary data; complete data pending | 2-year authorization (extendable) | Post-approval commitments |
Verification and Abridged reviews rely on prior assessments by Stringent Regulatory Authorities (SRAs), consistent with WHO principles on regulatory reliance. SFDA Verification & Abridged Guidance v2.2 These pathways were introduced in February 2017 to shorten timelines for products with existing FDA or EMA clearances. Hashan et al., 2015
Priority review, launched in October 2013 and implemented in February 2014, targets new chemical entities, biologicals, vaccines, and biosimilars that treat serious or life-threatening conditions. SFDA Priority Review Guidance v5.3 The program also covers shortage drugs and products on SFDA incentive lists. Under the priority procedure, assessment timelines drop by roughly 40%.
How Do SFDA Review Timelines Compare Globally?
A retrospective observational study published in 2026—authored by SFDA scientists—found that the median submission-to-approval time for novel drugs was 248 days at the SFDA, statistically tied with the FDA's 243-day median. Algabbani et al., 2026
The interquartile range (IQR) for SFDA approvals spanned 154 to 361 days, while the FDA's IQR ran from 183 to 359 days. Average approval time was 278.5 days (SD 176) at the SFDA versus 273.6 days (SD 114) at the FDA. These figures place the SFDA ahead of agencies such as Swissmedic (441 days) and the Pharmaceuticals and Medical Devices Agency (PMDA, 322 days) in the same comparison.
Among 48 novel drugs approved by the FDA in 2019, 21 (43.75%) had received SFDA approval by mid-2024. Algabbani et al., 2026 Small molecules dominated both portfolios: 58.33% of FDA approvals and 64% of SFDA approvals. Notably, advanced therapies such as gene therapies and synthetic peptide analogs were absent from the SFDA cohort, mainly attributed to non-submission rather than regulatory rejection.
What Is the Market Impact in Saudi Arabia?
The expedited framework has coincided with rapid expansion of the Saudi pharmaceutical registry. An observational study tracking SFDA approvals from 2011 to 2020 recorded a rise in total registered products from 5,498 to 10,424. Alhomaidan et al., 2023
New medication approvals grew from 21 in 2011 to 214 in 2021. Biological approvals climbed from 4 items to 86, while generic approvals surged from 59 to 533 over the same period. Alhomaidan et al., 2023
Review durations also fell sharply. The total days required for SFDA to assess new medications dropped from 191 in 2011 to 119 in 2021. For biologicals, review time fell from 378 days in 2016 to 105 days in 2021. Generic assessment time declined from a peak of 409 days in 2015 to 109 days in 2021. Alhomaidan et al., 2023 These gains stem in part from the reliance strategy implemented by late 2019, which cut average Gulf Centralised Procedure approval times from 838 calendar days in 2015 to 321 days in 2019. Hashan & Almutairi, 2022
Faster market entry has intensified competition among generic manufacturers and multinational innovators. The increased volume of approvals, however, also raises questions about post-market surveillance capacity, given that GMP inspection deficiencies in areas such as production, quality control, and premises remain common. Alhomaidan et al., 2023
Which Regulatory Milestones Shaped the Current Framework?
Several inflection points built the modern SFDA expedited system. The Authority introduced the Priority Review pathway in 2014, followed by the Verification and Abridged routes in February 2017. SFDA Priority Review Guidance v5.3 SFDA Verification & Abridged Guidance v2.2
In 2016, the SFDA mandated electronic Common Technical Document (eCTD) submissions, aligning dossier format with ICH standards. Membership in the International Council for Harmonisation (ICH) followed in 2021, signaling the Kingdom's intent to integrate global quality, safety, and efficacy benchmarks into national regulation. Algabbani et al., 2026
More recent additions include the Orphan Drug Designation program, launched in June 2023 for therapies targeting diseases with prevalence below 1 in 50,000, and the Breakthrough Medicines Program, rolled out in October 2023. SFDA BMP Guidance v1.0 The latter allows sponsors to submit designation requests by the end of Phase II, with scientific assessment targeted at 60 working days. Conditional approval, meanwhile, grants temporary two-year authorizations—extendable up to six years—when strong preliminary data support benefit over risk but the full dossier remains incomplete. SFDA Regulatory Framework v6.4
What Should Pharma Companies Watch Next?
Three developments will likely define the next phase of Saudi regulatory strategy. First, the SFDA is drafting frameworks for real-world data and real-world evidence, which could expand post-approval commitment pathways and support label updates without new randomized trials. Algabbani et al., 2026
Second, the gap in advanced therapies—gene therapies, synthetic peptides, and cell therapies—suggests either a need for targeted sponsor outreach or further refinement of the Breakthrough Medicines Program to attract earlier submissions. Third, continued growth in generic approvals will test the SFDA's inspection and pharmacovigilance bandwidth, particularly as the registry approaches 11,000 products.
Frequently Asked Questions
What are the SFDA's expedited drug approval pathways?
The SFDA's expedited pathways include Priority Review, Verification, Abridged, Breakthrough Medicines Program, Orphan Drug Designation, and Conditional Approval.
How much have review timelines been reduced by using SFDA expedited pathways?
Review timelines for priority cases have been reduced by up to 40%. The median approval time for drugs via SFDA expedited pathways is 248 days, closely aligning with the FDA's median approval time.
What percentage of novel drugs in Saudi Arabia are approved via expedited pathways?
52.17% of drug approvals in the studied cohort used an expedited review pathway, reflecting strong uptake of reliance-based and priority routes.
How does the SFDA's approval timeline compare to the FDA's?
The median approval time for drugs via SFDA expedited pathways is 248 days, closely aligning with the FDA's median approval time of 243 days.
Primary Sources
- Algabbani A, Hafiz R, AlWon B. The Saudi FDA drug evaluation timeline in comparison with international counterparts: a retrospective observational study. J Pharm Policy Pract. 2026. doi:10.1080/20523211.2025.2605398
- Alhomaidan AM, Alageel MA, Alrafie TA, et al. Trends in Saudi FDA drug approvals and GMP inspections: an observational study. GaBI Journal. 2023;12(3):76-86. doi:10.5639/gabij.2023.1203.013
- Saudi Food and Drug Authority. Guidance for Priority Review of Product Registration. Version 5.3. Issued 24 October 2013; updated 11 February 2024. sfda.gov.sa
- Saudi Food and Drug Authority. Registration According to Verification and Abridged. Version 2.2. Implemented 1 February 2017; updated 1 May 2024. sfda.gov.sa
- Saudi Food and Drug Authority. Regulatory Framework for Drugs Approval. Version 6.4. Implemented 1 October 2023; updated 11 June 2024. sfda.gov.sa
- Saudi Food and Drug Authority. Breakthrough Medicines Program. Version 1.0. sfda.gov.sa
- Hashan H, Aljuffali IA, Patel P, Walker S. The Saudi Arabia Food and Drug Authority: an evaluation of the registration process and good review practices. Pharm Med. 2015;29(6):365-377. doi:10.1007/s40290-015-0124-4
- Hashan H, Almutairi M. Regulatory review times in the Gulf Cooperation Council: impact of reliance procedures. Pharm Med. 2022;36(6):445-455. doi:10.1007/s40290-022-00432-0
Related Coverage
This article follows our editorial standards. Report a correction via editorial contact.
